Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Provider beliefs and practices relating to tobacco use in patients living with HIV/AIDS: a national survey.

Shuter J, Salmo LN, Shuter AD, Nivasch EC, Fazzari M, Moadel AB.

AIDS Behav. 2012 Feb;16(2):288-94. doi: 10.1007/s10461-011-9891-4.

2.

Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward.

Wolfe D, Carrieri MP, Shepard D.

Lancet. 2010 Jul 31;376(9738):355-66. doi: 10.1016/S0140-6736(10)60832-X. Review.

PMID:
20650513
3.

Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.

Knowlton AR, Arnsten JH, Eldred LJ, Wilkinson JD, Shade SB, Bohnert AS, Yang C, Wissow LS, Purcell DW.

AIDS Patient Care STDS. 2010 Jul;24(7):421-8. doi: 10.1089/apc.2009.0240.

4.

Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008.

Mehta SH, Kirk GD, Astemborski J, Galai N, Celentano DD.

Clin Infect Dis. 2010 Jun 15;50(12):1664-71. doi: 10.1086/652867.

5.

Social and structural determinants of HAART access and adherence among injection drug users.

Kr├╝si A, Wood E, Montaner J, Kerr T.

Int J Drug Policy. 2010 Jan;21(1):4-9. doi: 10.1016/j.drugpo.2009.08.003. Epub 2009 Sep 10.

PMID:
19747811
6.

Health-related beliefs and decisions about accessing HIV medical care among HIV-infected persons who are not receiving care.

Beer L, Fagan JL, Valverde E, Bertolli J; Never in Care Project.

AIDS Patient Care STDS. 2009 Sep;23(9):785-92. doi: 10.1089/apc.2009.0032.

PMID:
19645620
7.

Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004.

Grigoryan A, Hall HI, Durant T, Wei X.

PLoS One. 2009;4(2):e4445. doi: 10.1371/journal.pone.0004445. Epub 2009 Feb 13.

8.

The therapeutic implications of timely linkage and early retention in HIV care.

Ulett KB, Willig JH, Lin HY, Routman JS, Abroms S, Allison J, Chatham A, Raper JL, Saag MS, Mugavero MJ.

AIDS Patient Care STDS. 2009 Jan;23(1):41-9. doi: 10.1089/apc.2008.0132.

9.

HIV prevalence estimates--United States, 2006.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 Oct 3;57(39):1073-6.

10.

Highly active antiretroviral therapy and survival in HIV-infected injection drug users.

Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, Montaner JS.

JAMA. 2008 Aug 6;300(5):550-4. doi: 10.1001/jama.300.5.550.

PMID:
18677027
11.

Improving survival among HIV-infected injection drug users: how should we define success?

Kirk GD, Vlahov D.

Clin Infect Dis. 2007 Aug 1;45(3):377-80. Epub 2007 Jun 19. No abstract available.

12.
13.
14.

Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure.

Giordano TP, Visnegarwala F, White AC Jr, Troisi CL, Frankowski RF, Hartman CM, Grimes RM.

AIDS Care. 2005 Aug;17(6):773-83.

PMID:
16036264
15.

Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.

Wood E, Hogg RS, Yip B, Dong WW, Wynhoven B, Mo T, Brumme CJ, Montaner JS, Harrigan PR.

AIDS. 2005 Jul 22;19(11):1189-95.

PMID:
15990572
16.

Physician specialization and the quality of care for human immunodeficiency virus infection.

Landon BE, Wilson IB, McInnes K, Landrum MB, Hirschhorn LR, Marsden PV, Cleary PD.

Arch Intern Med. 2005 May 23;165(10):1133-9.

PMID:
15911726
17.

Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection.

Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM, Sterling TR.

Am J Epidemiol. 2005 Jun 1;161(11):999-1012.

18.

Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users.

Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD.

Arch Intern Med. 2005 Mar 28;165(6):618-23.

PMID:
15795336
19.

A national study of the relationship of care site HIV specialization to early adoption of highly active antiretroviral therapy.

Wilson IB, Landon BE, Ding L, Zaslavsky AM, Shapiro MF, Bozzette SA, Cleary PD.

Med Care. 2005 Jan;43(1):12-20.

PMID:
15626929
20.

Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users.

Loughlin A, Metsch L, Gardner L, Anderson-Mahoney P, Barrigan M, Strathdee S.

AIDS Care. 2004 May;16(4):485-500.

PMID:
15203416

Supplemental Content

Support Center